Literature DB >> 5492891

Mechanism of the hypotensive action of methyldopa in normal and immunosympathectomized rats.

E Ayitey-Smith, D R Varma.   

Abstract

1. The antihypertensive action of methyldopa was investigated in the light of the prevailing false sympathetic neurotransmitter hypothesis of Day & Rand (1963). Immunosympathectomized and normal animals were used for the investigation.2. Methyldopa in a single injection significantly decreased the blood pressure in control hypertensive, immunosympathectomized normotensive, and normal rats. Guanethidine did not decrease the blood pressure of immunosympathectomized rats; it decreased the blood pressure of control and control hypertensive rats.3. The hypotensive effect of methyldopa was not antagonized by adrenoceptor and ganglion blocking agents or by the inhibition of dopamine beta-oxidase.4. High doses of methyldopa produced less hypotension than relatively low doses. This might be due to an antagonism of the hypotensive effect by methylnoradrenaline, which is formed from methyldopa.5. The antihypertensive action of methyldopa could not be correlated with any change in aortic sodium or potassium.6. It is concluded that methyldopa does not exert its hypotensive effect by producing a weakly active false sympathetic neurotransmitter.

Entities:  

Mesh:

Substances:

Year:  1970        PMID: 5492891      PMCID: PMC1702886          DOI: 10.1111/j.1476-5381.1970.tb09912.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  17 in total

1.  Influence of an adrenergic beta-receptor blocking agent on the effect of various hypotensive agents in the hypertensive rat.

Authors:  H Brunner; P R Hedwall; M Meier
Journal:  Experientia       Date:  1965-04-15

2.  Antihypertensive effect of methyldopa in metacorticoid immunosympathectomized rats.

Authors:  D R Varma
Journal:  J Pharm Pharmacol       Date:  1967-01       Impact factor: 3.765

3.  Mode of action of methyldopa.

Authors:  M D Day; M J Rand
Journal:  J Pharm Pharmacol       Date:  1967-06       Impact factor: 3.765

4.  Blood pressure and noradrenaline levels after treatment with alpha-methyldopa, alpha-methyldopamine and alpha-methyl-m-tyrosine.

Authors:  M Henning
Journal:  J Pharm Pharmacol       Date:  1967-11       Impact factor: 3.765

5.  On the pharmacology of alpha-methylated catecholamines and the mechanism of the antihypertensive action of alpha-methyldopa.

Authors:  P Holtz; D Palm
Journal:  Life Sci       Date:  1967-09-01       Impact factor: 5.037

6.  Effect of methyldopa, reserpine and guanethidine on hindleg vascular resistance.

Authors:  S Mohammed; T E Gaffney; A C Yard; H Gomez
Journal:  J Pharmacol Exp Ther       Date:  1968-04       Impact factor: 4.030

7.  On the mechanism of action of hypotensive drugs.

Authors:  E Zaimis
Journal:  Proc R Soc Med       Date:  1965-12

8.  The physiologic disposition and metabolism of norepinephrine in immunosympathectomized animals.

Authors:  L L Iversen; J Glowinski; J Axelrod
Journal:  J Pharmacol Exp Ther       Date:  1966-02       Impact factor: 4.030

9.  [Demonstration of alpha-methylnoradrenaline in the urine of hypertensive patients treated with alpha-methyldopa].

Authors:  E Muscholl; K H Rahn
Journal:  Klin Wochenschr       Date:  1966-12-15

10.  Morphological, biochemical and functional changes in the sympathetic nervous system of rats treated with nerve growth factor-antiserum.

Authors:  E Zaimis; L Berk; B A Callingham
Journal:  Nature       Date:  1965-06-19       Impact factor: 49.962

View more
  3 in total

Review 1.  Antihypertensive drugs: clinical pharmacology and therapeutic use.

Authors:  G L Wollam; R W Gifford; R C Tarazi
Journal:  Drugs       Date:  1977-12       Impact factor: 9.546

2.  Further evidence for a central hypotensive action of alpha-methyldopa in both the rat and cat.

Authors:  L Finch; G Haeusler
Journal:  Br J Pharmacol       Date:  1973-02       Impact factor: 8.739

3.  The influence of SK & F 64139, a phenylethanolamine-N-methyltransferase inhibitor, on centrally mediated cardiovascular effects of alpha-methyldopa and clonidine.

Authors:  M Gerold; G Haeusler
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1982-12       Impact factor: 3.000

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.